Browse Drug Recalls
1,040 FDA drug safety recalls.
FDA Drug Recall Enforcement Database
Browse 1,040 FDA drug recall enforcement actions. Each entry includes the product description, reason for recall, classification (Class I through III based on severity), recalling firm, and distribution details. Use the filters below to search by year, classification, state, or keyword.
Drug Safety Recalls
Browse 1,040 FDA drug recalls in NY.
| Date | Product | Reason | Class | Firm |
|---|---|---|---|---|
| Jun 5, 2019 | Cetirizine Oral Solution 1 mg/mL, Up & Up, Children's allergy relief, Antihis... | cGMP Deviations: Firm was notified by their supplier of Cetirizine HCL Oral Solution, USP, 1mg/mL... | Class II | P & L Developments, LLC |
| May 31, 2019 | Preferred Plus Pharmacy Iron Elixir Ferrous Sulfate, 220 mg, 16 fl oz. (473 m... | cGMP Deviations: Products may have microbial contamination. | Class II | Geritrex, LLC |
| May 31, 2019 | Ritussin DM Children & Adults, 4 Fl. Oz. (118 mL), RIJ Pharmaceutical Corpora... | cGMP Deviations: Products may have microbial contamination. | Class II | Geritrex, LLC |
| May 31, 2019 | Ritussin DM Double Strength, 4 FL. OZ. (118 mL), RIJ Pharmaceutical Corporati... | cGMP Deviations: Products may have microbial contamination. | Class II | Geritrex, LLC |
| May 31, 2019 | Gericare Iron Supplement Elixir Ferrous Sulfate, 220 mg, 16 fl oz. (473 mL), ... | cGMP Deviations: Products may have microbial contamination. | Class II | Geritrex, LLC |
| May 31, 2019 | Diphenhydramine Oral Liquid Alcohol Free, 12.5 mg/5 mL, 4 fl oz (118 mL), RIJ... | cGMP Deviations: Products may have microbial contamination. | Class II | Geritrex, LLC |
| May 31, 2019 | Gericare Diocto Liquid Docusate Sodium Stool Softener, 50 mg/5mL, 16 FL OZ (4... | cGMP Deviations: Products may have microbial contamination. | Class II | Geritrex, LLC |
| May 31, 2019 | Gericare Geri-Tussin DM, 16 FL OZ (473 mL), Geri-care Phamaceuticals Corp. 16... | cGMP Deviations: Products may have microbial contamination. | Class II | Geritrex, LLC |
| May 31, 2019 | Preferred Plus Dioctyl Liquid Stool Softener (Docusate Sodium), 50mg/5mL, 16 ... | cGMP Deviations: Products may have microbial contamination. | Class II | Geritrex, LLC |
| May 22, 2019 | Ondansetron Injection, USP, 40 mg / 20 mL, 20 mL vial, Rx Only, Fresenius Kab... | Failed Impurities/Degradation Specifications. | Class III | Fresenius Kabi USA, LLC |
| May 6, 2019 | Senna (sennosides 8.8 mg) Syrup, 8 fl oz. (237 mL) bottles, Rij Pharmaceutica... | Failed Impurities/Degradation Specifications: Atypical odor and unpleasant taste was reported | Class II | Geritrex, LLC |
| May 6, 2019 | Senna (sennosides 8.8 mg) Syrup 8 fl oz. (236 mL) bottles, Distributed by Ger... | Failed Impurities/Degradation Specifications: Atypical odor and unpleasant taste was reported | Class II | Geritrex, LLC |
| Apr 30, 2019 | Mycophenolate Mofetil for Injection, USP 500 mg, 4 Single Dose Vials, Rx Onl... | Presence of Particulate Matter; glass fragment observed in one vial of reconstituted product | Class I | Par Pharmaceutical, Inc. |
| Apr 29, 2019 | Relpax (eletriptan HBr) 40 mg, a) 12 tablets 2 cards x six 40 mg tablets per ... | Labeling: Label Error on Declared Strength: an artwork error on the secondary packaging of Relpax... | Class III | Pfizer Inc. |
| Mar 29, 2019 | Clonidine HCL Injection, 1000 mcg/10mL (100 mcg/mL), 10 ML Single Dose Vial, ... | Labeling: Label Error on Declared Strength: Side carton panel incorrectly lists the concentration... | Class III | X-Gen Pharmaceuticals Inc. |
| Mar 22, 2019 | Testosterone Cypionate Injection, USP, 200 mg/mL, For IM use only, 1 mL Vial,... | Presence of Particulate Matter. | Class II | InvaGen Pharmaceuticals, Inc. |
| Mar 22, 2019 | Testosterone Cypionate Injection, USP, 2000 mg/10 mL (200 mg/mL), For intramu... | Presence of Particulate Matter. | Class II | InvaGen Pharmaceuticals, Inc. |
| Mar 22, 2019 | Testosterone Cypionate Injection, USP, 1000 mg/10 mL (100 mg/mL), For intramu... | Presence of Particulate Matter. | Class II | InvaGen Pharmaceuticals, Inc. |
| Mar 15, 2019 | Cleocin Phosphate (clindamycin injection), USP, 300 mg/ 2 mL (150 mg/mL), 2 m... | Failed Impurities/Degradation Specifications: High out-of-specification (OOS) results were demons... | Class III | Pfizer Inc. |
| Mar 15, 2019 | Cleocin Phosphate, clindamycin injection, USP, 600 mg/ 4 mL (150 mg/mL), 4 mL... | Failed Impurities/Degradation Specifications: High out-of-specification (OOS) results were demons... | Class III | Pfizer Inc. |
| Mar 15, 2019 | Clindamycin Injection, USP, 300 mg/ 2 mL (150 mg/mL), 2 mL vials, Rx only, Di... | Failed Impurities/Degradation Specifications: High out-of-specification (OOS) results were demons... | Class III | Pfizer Inc. |
| Mar 15, 2019 | Clindamycin Injection, USP, 900 mg/6 mL (150 mg/mL), 6 mL vial, Rx only, Dist... | Failed Impurities/Degradation Specifications: High out-of-specification (OOS) results were demons... | Class III | Pfizer Inc. |
| Mar 15, 2019 | Repairwear Laser Focus Line Smoothing Cream Broad Spectrum SPF 15, packaged i... | Defective container: Ineffective seal between the cap and jar of the affected product. | Class III | Estee Lauder Inc |
| Mar 15, 2019 | Clindamycin Injection, USP, 600 mg/ 4 mL (150 mg/mL), 4 mL vials, Rx only, Di... | Failed Impurities/Degradation Specifications: High out-of-specification (OOS) results were demons... | Class III | Pfizer Inc. |
| Mar 15, 2019 | 8.4% Sodium Bicarbonate Injection, USP 50 mEq (1 mEq/mL) 4.2 grams (84 mg/mL)... | Presence of Particulate Matter; glass particulates | Class I | Pfizer Inc. |
| Mar 15, 2019 | Cleocin Phosphate, clindamycin injection, USP, 900 mg/ 6 mL (150 mg/mL), 6 mL... | Failed Impurities/Degradation Specifications: High out-of-specification (OOS) results were demons... | Class III | Pfizer Inc. |
| Mar 7, 2019 | Little Remedies New Baby Essentials Kit. Each kit contains 1 each of the foll... | Incorrect/undeclared excipients: Kit carton bear incorrect labeling for two of the five items con... | Class II | Medtech Products, Inc. |
| Mar 5, 2019 | LEOPARD Miracle Honey packaged in a wooden box, UPC 8 699415 910534, containi... | Marketed Without An Approved NDA/ANDA: product tainted with undeclared sildenafil, an FDA approve... | Class I | USA LESS Inc. |
| Feb 13, 2019 | Ciclopirox shampoo 1%,120 mL bottle, Rx only, Manufactured By Perrigo Bronx, ... | Failed Degradation/Impurities Specifications: Out of specification related substance results duri... | Class III | Perrigo New York, Inc. |
| Dec 6, 2018 | Levoxyl (levothyroxine sodium tablets, USP) tablets 112 mcg, 100-count bottle... | Superpotent Drug. | Class II | Pfizer Inc. |
| Dec 4, 2018 | Estradiol Tablets, USP, 2 mg, 100-count bottle, Rx Only, Distributed by: Epic... | Presence of foreign tablet/capsule: A single foreign tablet was found in pharmacy dispensed bottl... | Class II | Epic Pharma, LLC |
| Nov 15, 2018 | SODIUM CHLORIDE INJECTION, USP, 0.9%, 10 mL Single Dose Vial, packaged in a 2... | Labeling Not Elsewhere Classified: Fresenius Kabi is taking this action due to an incorrect state... | Class I | Fresenius Kabi USA, LLC |
| Nov 15, 2018 | SODIUM CHLORIDE INJECTION, USP, 0.9%, 20 mL Single Dose Vial, packaged in a 2... | Labeling Not Elsewhere Classified: Fresenius Kabi is taking this action due to an incorrect state... | Class I | Fresenius Kabi USA, LLC |
| Oct 29, 2018 | Westminister Irbesartan Tablets, USP, 300mg, Rx Only,(a) 30-count bottle (NDC... | CGMP Deviations: FDA laboratory testing confirmed presence of an impurity, N-nitrosodimethylamine... | Class II | Sciegen Pharmaceuticals Inc |
| Oct 29, 2018 | GSMS Irbesartan Tablets, USP, 300 mg,(a) 30-count bottle (NDC 60429-642-30), ... | CGMP Deviations: FDA laboratory testing confirmed presence of an impurity, N-nitrosodimethylamine... | Class II | Sciegen Pharmaceuticals Inc |
| Oct 29, 2018 | GSMS Irbesartan Tablets, USP, 75 mg, 30-count bottle, Rx Only, Manufactured b... | CGMP Deviations: FDA laboratory testing confirmed presence of an impurity, N-nitrosodimethylamine... | Class II | Sciegen Pharmaceuticals Inc |
| Oct 29, 2018 | Westminister Irbesartan Tablets, USP, 150 mg, (a) 30-count bottle (NDC 69367-... | CGMP Deviations: FDA laboratory testing confirmed presence of an impurity, N-nitrosodimethylamine... | Class II | Sciegen Pharmaceuticals Inc |
| Oct 29, 2018 | GSMS Irbesartan Tablets, USP, 150 mg, (a) 30-count bottle (NDC 60429-641-30),... | CGMP Deviations: FDA laboratory testing confirmed presence of an impurity, N-nitrosodimethylamine... | Class II | Sciegen Pharmaceuticals Inc |
| Oct 29, 2018 | Westminister Irbesartan Tablets, USP, 75 mg (a) 30-count bottle (NDC 69367-11... | CGMP Deviations: FDA laboratory testing confirmed presence of an impurity, N-nitrosodimethylamine... | Class II | Sciegen Pharmaceuticals Inc |
| Oct 19, 2018 | Children's 24 Hour Allergy (cetirizine hydrochloride) Oral Solution 1 mg/mL, ... | Failed Impurities/Degradation Specifications: unknown impurity higher than the specified limit wa... | Class II | Taro Pharmaceuticals U.S.A., Inc. |
| Oct 19, 2018 | children's allergy relief (cetirizine hydrochloride) oral solution, 1 mg/mL, ... | Failed Impurities/Degradation Specifications: unknown impurity higher than the specified limit wa... | Class II | Taro Pharmaceuticals U.S.A., Inc. |
| Oct 19, 2018 | children's allergy (cetirizine hydrochloride) Oral Solution, 1 mg/mL, ANTIHIS... | Failed Impurities/Degradation Specifications: unknown impurity higher than the specified limit wa... | Class II | Taro Pharmaceuticals U.S.A., Inc. |
| Oct 3, 2018 | Magnesium Sulfate in Water for Injection (0.325 mEq Mg++/mL) 40 mg/mL, 20 g T... | Correct Labeled Product Mispack: confirmed report involving a single unit of properly labeled Hep... | Class II | Pfizer Inc. |
| Oct 3, 2018 | Amlodipine Besylate USP 10 mg Tablets, 1000-count bottles, Rx Only, Manufactu... | Subpotent Drug: One lot of product does not meet the product specification for Assay test at 3 mo... | Class III | InvaGen Pharmaceuticals, Inc. |
| Sep 20, 2018 | Glipizide XL (glipizide) extended-release tablets 5 mg 500-tablet bottle, Rx ... | CGMP Deviations; rejected product was used to manufacture final bulk lot | Class II | Pfizer Inc. |
| Sep 20, 2018 | Meropenem for Injection, USA (I.V.), 1 gram/vial, 25 vials per carton, Steril... | Lack of assurance of sterility: loss of container integrity. | Class II | Pfizer Inc. |
| Sep 19, 2018 | Elelyso (taliglucerase alfa) for injection, 200 units/vial, single-use vial, ... | Lack of assurance of sterility -Reports of loose metal ferrule crimps on vials for injection. Th... | Class II | Pfizer Inc. |
| Sep 6, 2018 | Pramipexole dihydrochloride extended release tablets, 0.75 mg, packaged in 30... | Failed impurities/degradation specifications: Finished product contain a known product impurity a... | Class III | Par Pharmaceutical, Inc. |
| Sep 6, 2018 | Bupropion Hydrochloride ER Tablets, USP 150 mg, packaged in a) 90-count bottl... | Failed impurities/ degradation specifications: Out-of-specification results were observed in the ... | Class III | InvaGen Pharmaceuticals, Inc. |
| Aug 28, 2018 | Argatroban Injection, 250 mg/2.5 mL (100 mg/mL), 2.5 mL Single-use Vial, Rx o... | Failed Impurities/Degradation Specifications; Out of specification stability testing results at t... | Class III | Pfizer Inc. |
Frequently Asked Questions
When a drug safety issue is identified, through FDA inspections, laboratory testing, adverse event reports, or manufacturer quality checks, the responsible company issues a recall to remove the affected products from the market. Pharmacies pull the product from shelves, and consumers are advised to contact their healthcare provider for alternatives.
The leading causes include cGMP deviations, impurity contamination (including nitrosamines like NDMA), failed dissolution or stability testing, sterility issues, potency problems, labeling errors, and foreign particle contamination.
Use the search and filter tools on this page to look up specific medications, active ingredients, or manufacturers. Each recall entry includes the product description, lot numbers, and distribution details.